Jun 2026 (Q2 FY26) — Aug 4, 2026
LeMaitre Vascular Q2 FY26 — Strong Organic Growth Despite Headwinds, Artegraft Drives International Expansion
Read the full callLeMaitre Vascular (LMAT) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
LeMaitre Vascular earnings: last reported Tue, 4 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 70.4 | +9.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 29.0 | +3.9 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 17.1 | +23.7% YoY | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. |
Price
$82.31 +1.84% · +$1.49
Performance −5.0% 1Y
1Y: $86.6 on 17 Oct 2025 → $82.31. High $117.39 (14 Apr 2026), low $78.8 (10 Sept 2026).
- Previous close
- $80.82
- 52-week range
- $78.8 – $117.39
- One year
- −6.48%
Overview
- Symbol
- LMAT
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
LeMaitre Vascular earnings calls (LMAT)
Financials
What the filings say
Net profit, year on year: +24% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 55 | 56 | 60 | 64 | 61 | 64 | 67 | 70 |
| Operating profit | 13 | 13 | 13 | 16 | 20 | 19 | 18 | 20 |
| Operating margin | 24.0% | 23.1% | 21.1% | 25.1% | 33.3% | 29.2% | 26.7% | 29.0% |
| Interest | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 15 | 14 | 14 | 18 | 23 | 20 | 20 | 22 |
| Tax rate | 23.4% | 20.2% | 22.7% | 23.8% | 23.1% | 23.2% | 20.3% | 23.2% |
| Net profit | 11 | 11 | 11 | 14 | 17 | 16 | 16 | 17 |
| EPS ($ per share) | 0.50 | — | 0.49 | 0.61 | 0.77 | — | 0.69 | 0.75 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | 46 | 57 | 71 | 88 | 98 | 115 | 145 | 185 |
| Total liabilities | 23 | 40 | 80 | 39 | 42 | 49 | 215 | 222 |
| Fixed assets | 14 | 15 | 15 | 17 | 18 | 22 | 25 | 27 |
| Total assets | 153 | 188 | 253 | 293 | 310 | 347 | 552 | 616 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 20 | 14 | 35 | 35 | 25 | 37 | 44 | 81 |
| Cash from investing | -7 | -24 | -53 | -61 | -10 | -25 | -200 | -65 |
| Cash from financing | -4 | -5 | 32 | 14 | -9 | -7 | 158 | -15 |
| Net cash flow | 7 | -15 | 15 | -13 | 5 | 5 | 1 | 3 |
| Capital expenditure | -3 | -4 | -3 | -5 | -3 | -7 | -7 | -7 |
| Free cash flow | 16 | 10 | 32 | 30 | 22 | 29 | 37 | 74 |
Insider filings
145 filings between Nov 20, 2025 and Sep 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$30.04M
11 sales by 5 insiders
18% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 22
- Award — granted as compensation
- 81
- Option exercise — converted options into shares
- 27
- Tax withheld — shares kept back by the company to cover tax
Also filed: 4 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| LeMaitre George W | — | $27.08M | May 8, 2026 |
| Roberts David B | — | $1.26M | Mar 11, 2026 |
| Kamke Trent G | — | $713.2K | May 8, 2026 |
| Ross Bridget A | — | $560.4K | May 7, 2026 |
| Jasinski Lawrence J | — | $433.7K | May 7, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 1, 2026 | Roush John A Director | Option exercise | 3,444 | $167.4K |
| Jun 4, 2026 | LeMaitre George W Chairman and CEO | Gift | 11,974 | $0 |
| Jun 4, 2026 | LeMaitre George W Chairman and CEO | Award | 11,974 | $0 |
| May 8, 2026 | Kamke Trent G Senior V. P., Operations | Sale | 2,928 | $313.3K |
| May 8, 2026 | LeMaitre George W Chairman and CEO | Sale | 27,881 | $3.03M |
| May 7, 2026 | Ross Bridget A Director | Option exercise | 3,444 | $167.4K |
| May 7, 2026 | Jasinski Lawrence J Director | Sale | 3,943 | $433.7K |
| May 7, 2026 | Jasinski Lawrence J Director | Option exercise | 1,069 | $50.4K |
| May 7, 2026 | Jasinski Lawrence J Director | Option exercise | 924 | $50.5K |
| May 7, 2026 | LeMaitre George W Chairman and CEO | Sale | 18,600 | $2.00M |
| May 7, 2026 | Ross Bridget A Director | Sale | 5,044 | $560.4K |
| May 7, 2026 | Jasinski Lawrence J Director | Option exercise | 865 | $87.5K |
| May 7, 2026 | Ross Bridget A Director | Option exercise | 1,600 | $75.5K |
| Apr 22, 2026 | Pellegrino Joseph P JR Director | Option exercise | 2,941 | $104.3K |
| Mar 11, 2026 | Kamke Trent G Senior V. P., Operations | Option exercise | 2,625 | $93.1K |
| Mar 11, 2026 | Kamke Trent G Senior V. P., Operations | Sale | 2,625 | $284.8K |
| Mar 11, 2026 | Roberts David B President and Director | Sale | 3,312 | $356.6K |
| Mar 10, 2026 | LeBlanc Dorian Paul Chief Financial Officer | Option exercise | 2 | $0 |
| Mar 10, 2026 | LeBlanc Dorian Paul Chief Financial Officer | Tax withheld | 96 | $10.5K |
| Mar 2, 2026 | LeMaitre George W Chairman and CEO | Sale 10b5-1 plan | 55,930 | $6.03M |
| Mar 2, 2026 | LeMaitre George W Chairman and CEO | Gift 10b5-1 plan | 5,000 | $0 |
| Feb 27, 2026 | Kamke Trent G Senior V. P., Operations | Sale | 1,044 | $115.1K |
| Feb 27, 2026 | Roberts David B President and Director | Sale | 8,464 | $904.0K |
| Feb 26, 2026 | Kamke Trent G Senior V. P., Operations | Award | 1,051 | $0 |
| Feb 26, 2026 | Roberts David B President and Director | Tax withheld | 13 | $1.5K |
| Feb 26, 2026 | Roberts David B President and Director | Tax withheld | 134 | $15.2K |
| Feb 26, 2026 | Roberts David B President and Director | Option exercise | 3 | $0 |
| Feb 26, 2026 | Roberts David B President and Director | Award | 1,514 | $0 |
| Feb 26, 2026 | Roberts David B President and Director | Award | 146 | $0 |
| Feb 26, 2026 | LeMaitre George W Chairman and CEO | Tax withheld 10b5-1 plan | 496 | $56.4K |
| Feb 26, 2026 | Roush John A Director | Option exercise | 1 | $0 |
| Feb 26, 2026 | LeMaitre George W Chairman and CEO | Option exercise 10b5-1 plan | 13 | $0 |
| Feb 26, 2026 | Ross Bridget A Director | Option exercise | 1 | $0 |
| Feb 26, 2026 | Ross Bridget A Director | Award | 476 | $0 |
| Feb 26, 2026 | O'Connor John James Director | Option exercise | 1 | $0 |
| Feb 26, 2026 | LeMaitre George W Chairman and CEO | Award 10b5-1 plan | 5,609 | $0 |
| Feb 26, 2026 | O'Connor John James Director | Award | 476 | $0 |
| Feb 26, 2026 | Jasinski Lawrence J Director | Option exercise | 1 | $0 |
| Feb 26, 2026 | Jasinski Lawrence J Director | Award | 476 | $0 |
| Feb 26, 2026 | Pellegrino Joseph P JR Director | Option exercise | 4 | $0 |
| Feb 26, 2026 | Pellegrino Joseph P JR Director | Award | 1,893 | $0 |
| Feb 26, 2026 | Roush John A Director | Award | 476 | $0 |
| Feb 26, 2026 | Kamke Trent G Senior V. P., Operations | Tax withheld | 93 | $10.6K |
| Feb 26, 2026 | SHADAN MARTHA Director | Award | 476 | $0 |
| Feb 26, 2026 | Kamke Trent G Senior V. P., Operations | Option exercise | 2 | $0 |
| Feb 26, 2026 | SHADAN MARTHA Director | Option exercise | 1 | $0 |
| Feb 26, 2026 | LeMaitre George W Chairman and CEO | Sale 10b5-1 plan | 150,000 | $16.01M |
| Feb 5, 2026 | Roberts David B President and Director | Option exercise | 7 | $340 |
| Feb 5, 2026 | Roberts David B President and Director | Option exercise | 2,672 | $99.6K |
| Jan 8, 2026 | Kamke Trent G Senior V. P., Operations | Option exercise | 1,115 | $54.2K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for LEMAITRE VASCULAR INC
Free account. Everything above stays public.
Write why you follow LEMAITRE VASCULAR INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading